Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer.
Sign Up to like & getrecommendations! Published in 2021 at "Gynecologic oncology"
DOI: 10.1016/j.ygyno.2021.08.018
Abstract: OBJECTIVE This phase II clinical trial evaluated the safety and antitumor activity of balstilimab, an anti-PD-1 antibody, in patients with previously-treated, recurrent/metastatic cervical cancer. METHODS Eligible patients were 18 years or older with recurrent and/or metastatic… read more here.
Keywords: recurrent metastatic; metastatic cervical; safety; cervical cancer ... See more keywords